JP2023545009A5 - - Google Patents
Info
- Publication number
- JP2023545009A5 JP2023545009A5 JP2023520312A JP2023520312A JP2023545009A5 JP 2023545009 A5 JP2023545009 A5 JP 2023545009A5 JP 2023520312 A JP2023520312 A JP 2023520312A JP 2023520312 A JP2023520312 A JP 2023520312A JP 2023545009 A5 JP2023545009 A5 JP 2023545009A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antigen
- vaccine
- protein
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063087118P | 2020-10-02 | 2020-10-02 | |
| US63/087,118 | 2020-10-02 | ||
| PCT/US2021/053275 WO2022072910A1 (en) | 2020-10-02 | 2021-10-02 | Polynucleotide vaccines and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023545009A JP2023545009A (ja) | 2023-10-26 |
| JP2023545009A5 true JP2023545009A5 (cg-RX-API-DMAC7.html) | 2024-10-09 |
Family
ID=80950948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520312A Abandoned JP2023545009A (ja) | 2020-10-02 | 2021-10-02 | ポリヌクレオチドワクチンおよびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250213679A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4221739A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023545009A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230127977A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116916949A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021355496A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3197650A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022072910A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022009688A (es) | 2020-02-07 | 2022-12-15 | Rnaimmune Inc | Composición y métodos de vacunas de arnm contra la nueva infección por coronavirus. |
| TW202328166A (zh) | 2021-08-11 | 2023-07-16 | 美商達冕生物有限公司 | 針對新型冠狀病毒感染之mRNA疫苗之組成物及方法 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| CN114736925B (zh) * | 2022-04-21 | 2025-03-04 | 奥明(杭州)生物医药有限公司 | 用于病毒感染所致癌症的环形mRNA疫苗开发平台 |
| WO2024097259A1 (en) * | 2022-11-01 | 2024-05-10 | RNAimmune, Inc. | Composition and methods for mrna vaccines against novel omicron coronavirus infections |
| WO2024163503A1 (en) * | 2023-01-31 | 2024-08-08 | Imunon, Inc. | Process for producing dna formulations with lipopolymer delivery systems |
| KR102752534B1 (ko) * | 2023-10-04 | 2025-01-10 | 국방과학연구소 | 탄저균 및 보툴리눔 독소 a형의 동시 방어용 복합 항원 발현벡터, 및 이를 포함한 유전자 백신 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1262898B (it) * | 1992-03-23 | 1996-07-22 | Antigeni ricombinanti proteici ad aumentata immunogenicita' contenenti il peptide rappresentato dalla sequenza vqgeesndk | |
| WO2000040273A2 (en) * | 1999-01-08 | 2000-07-13 | Vical Incorporated | Treatment of viral diseases using an interferon omega expressing polynucleotide |
| EP1278551A2 (en) * | 2000-04-21 | 2003-01-29 | Vical Incorporated | Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics |
| US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
| WO2009108891A2 (en) * | 2008-02-29 | 2009-09-03 | Egen, Inc. | Modified poloxamers for gene expression and associated methods |
| TW201718001A (zh) * | 2015-07-31 | 2017-06-01 | 拜耳動物保健有限公司 | 豬物種中增強之免疫反應 |
-
2021
- 2021-10-02 CA CA3197650A patent/CA3197650A1/en active Pending
- 2021-10-02 KR KR1020237014741A patent/KR20230127977A/ko active Pending
- 2021-10-02 AU AU2021355496A patent/AU2021355496A1/en active Pending
- 2021-10-02 US US18/247,588 patent/US20250213679A1/en not_active Abandoned
- 2021-10-02 EP EP21876646.7A patent/EP4221739A4/en not_active Withdrawn
- 2021-10-02 JP JP2023520312A patent/JP2023545009A/ja not_active Abandoned
- 2021-10-02 CN CN202180081155.0A patent/CN116916949A/zh active Pending
- 2021-10-02 WO PCT/US2021/053275 patent/WO2022072910A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Berglund et al. | Enhancing immune responses using suicidal DNA vaccines | |
| US6964762B2 (en) | Composition and method for stimulating immune response to pathogen using complex adenoviral vector | |
| US7528223B2 (en) | Antigens encoded by alternative reading frames from pathogenic viruses | |
| Rajčáni et al. | Current developments in viral DNA vaccines: shall they solve the unsolved? | |
| US20020155127A1 (en) | Genetic vaccine against human immunodeficiency virus | |
| JP2023545009A (ja) | ポリヌクレオチドワクチンおよびその使用方法 | |
| US7754201B2 (en) | Method of vaccination through serotype rotation | |
| JP2024511356A5 (cg-RX-API-DMAC7.html) | ||
| JP2011088864A (ja) | インフルエンザウイルスに対するベクターワクチン | |
| US20130302368A1 (en) | Advanced Prime and Boost Vaccine | |
| Chunling et al. | Enhanced induction of SARS-CoV nucleocapsid protein-specific immune response using DNA vaccination followed by adenovirus boosting in BALB/c mice | |
| CA2325345A1 (en) | Medicaments for inducing cytotoxic t-cells | |
| CN1269524C (zh) | 胸腺素强化的遗传免疫方法 | |
| JP5635950B2 (ja) | 免疫原性組成物および方法 | |
| AU2007203565B2 (en) | Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens | |
| JP5898324B2 (ja) | 改良型hcvワクチンおよびその使用方法 | |
| Seth et al. | Development of Indian HIV-1 Subtype C Vaccine Candidates | |
| Seth | HIV-1 subtype C vaccine: waiting in wings for the human trials | |
| NZ781654A (en) | Vaccines against hepatitis b virus | |
| AU2002348154A1 (en) | Genetic vaccine against human immunodeficiency virus |